Form 4: Fate Therapeutics Executive Receives Stock Grants with Time-Based and Performance-Based Vesting

Bahram Valamehr, Chief R&D Officer of Fate Therapeutics, was granted 200,000 shares of common stock through a restricted stock unit award with both time-based and performance-based vesting conditions.

Summary

• Bahram Valamehr, Chief R&D Officer at Fate Therapeutics, received a grant of 200,000 shares of common stock on July 29, 2024.
• The grant is structured as a restricted stock unit (RSU) award.
• 100,000 of the units are subject to time-based vesting, while the other 100,000 are subject to performance-based vesting.
• 25,000 time-based units will vest on August 1, 2025, and 75,000 time-based units will vest on August 1, 2026, contingent on continued employment.
• The performance-based units vest based on the achievement of specified late-stage clinical and regulatory milestones by July 29, 2028.
• Half of the performance-based units will vest one year after two of three milestones are achieved, and the remaining half will vest one year after all three milestones are achieved, also contingent on continued employment.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, incentivizing performance and retention. It's generally positive as it aligns management with shareholder interests, but the vesting is subject to risks associated with clinical development and continued employment.

Positives

• The vesting schedule is designed to incentivize the Chief R&D Officer to remain with the company and achieve key clinical and regulatory milestones.
• The performance-based vesting aligns the executive's interests with the company's success in late-stage clinical development and regulatory approvals.

Risks

• The performance-based vesting is contingent on achieving specific clinical and regulatory milestones by July 29, 2028, which may not be met.
• The vesting is also contingent on the executive's continued employment, creating a risk if the executive leaves the company before the vesting dates.

Future Outlook

The vesting of the restricted stock units is contingent on continued employment and the achievement of clinical and regulatory milestones, indicating a focus on long-term performance and retention of key personnel.

Industry Context

Stock grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders and incentivize long-term value creation. The inclusion of performance-based vesting is typical for companies focused on clinical development and regulatory approvals.

Comparison to Industry Standards

• Many biotech companies, such as CRISPR Therapeutics, Beam Therapeutics, and Intellia Therapeutics, utilize similar stock-based compensation plans with vesting schedules tied to both time and the achievement of clinical and regulatory milestones.
• The specific milestones and vesting terms vary depending on the company's stage of development, pipeline, and strategic goals.
• The size of the grant is likely benchmarked against peer companies and the executive's role and responsibilities.

Stakeholder Impact

• Shareholders: The stock grant aligns management's interests with shareholder value creation.
• Employees: The grant may serve as a positive signal regarding the company's commitment to its leadership team.
• Executive: The grant provides a significant incentive for the executive to drive the company's success.

Next Steps

• The executive must continue employment with Fate Therapeutics to vest in the time-based units.
• Fate Therapeutics must achieve specified late-stage clinical and regulatory milestones by July 29, 2028, for the performance-based units to vest.

Key Dates